Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce

In a melodramatic reversal of fortune, Hims & Hers Health (NYSE:HIMS) has been rescued by the precise institution that astir sank it. Novo Nordisk (NYSE:NVO), which sued the telehealth supplier conscionable past period implicit copycat compounded GLP-1 drugs, has present agreed to spouse with Hims to merchantability its branded obesity medications -- including Wegovy and Ozempic -- straight done the platform. The woody is expected to beryllium announced arsenic soon arsenic Monday, ending the bitter ineligible feud and restoring a captious gross watercourse that Hims had mislaid erstwhile their archetypal collaboration collapsed past year.

Hims shares surged astir 40% successful aftermarket trading, erasing months of symptom and signaling Wall Street’s alleviation that the company’s maturation motor is backmost online. What looked similar a dilatory decease by regulatory unit and mislaid momentum has abruptly go a 2nd act. Novo Nordisk, erstwhile Hims’ aggressor, is present its savior.

Hims & Hers roseate similar a rocket during the telehealth boom. What began arsenic a level for hair-loss treatments, erectile dysfunction meds, and skincare evolved into a weight-loss powerhouse erstwhile GLP-1 agonists exploded successful popularity. During the acute shortage of Wegovy and Ozempic successful 2023–2024, Hims capitalized by offering compounded semaglutide versions astatine little prices and faster delivery. New customers flooded in, subscriptions soared, and the banal deed all-time highs astir a twelvemonth agone arsenic investors stake connected endless request for obesity drugs.

READ: The expert who called NVIDIA successful 2010 just named his apical 10 AI stocks

That stake unraveled fast. As the FDA declared the semaglutide shortage over, Novo Nordisk turned hostile. Last April's concern to grow Wegovy entree via telehealth lasted lone until June, erstwhile Novo abruptly terminated the deal, citing information concerns implicit Hims’ compounded products. The existent hammer came past month: Novo sued for patent infringement aft Hims launched a $49 compounded oral pill mimicking Novo’s caller formulation. Hims pulled the merchandise nether FDA pressure.

Compounding the harm were parallel regulatory clouds -- an SEC probe into Hims’ selling practices and whispers of a imaginable Justice Dept. probe into the information and legality of compounded GLP-1s. Investors fled. From its peak, the banal cratered 77%, wiping retired billions successful marketplace worth and leaving Hims staring astatine a aboriginal of slowed maturation and constricted upside without the GLP-1 tailwind.